Single Domain Antibody (SdAb) based Antibody-Drug Conjugate (ADC) Development Solution
SdAb-based ADC Development Workflow Features Case Study
Creative Biolabs is dedicated to discovering unique single domain antibodies for our clientele all over the world. We are now offering sdAb-based antibody-drug conjugate (ADC) development service and our scientists have built up end-to-end
solutions to generate high-quality sdAb-based ADC with complete technical support.
Antibody-drug conjugates (ADCs) have pioneered a novel domain in targeted therapeutics by integrating the precise targeting capabilities of biologics with the potent cytotoxic effects of small molecule drugs. To date, several ADCs that rely on full-sized
antibodies have been FDA approved and with a large pipeline in clinical trials. However, the complex structure of full-sized antibodies makes it hard to penetrate deeply into tumor tissues, limiting the therapeutic effect of ADCs.
Developing High-Quality SdAb-based ADC at Creative Biolabs
At present, Creative Biolabs provides a new solution to this challenge by utilizing single domain antibodies (sdAbs) instead of full-length IgG or other antibody fragments for the development of novel antibody-drug conjugates (ADCs). sdAb has the smallest
size (15 kDa) among all types of antibody analogs while containing the full antigen-binding domains. The small size endows sdAbs with the capability of epitope recognition when target antigens are densely packed and cryptic. Moreover, sdAbs have remarkable
tissue penetration due to their relatively small molecular size and compact spatial structure. Moreover, their single-domain structure facilitates efficient phagemid-based screening and offers extensive opportunities for site-specific modifications
without affecting the binding properties of the modified sdAbs.
Collectively, sdAb-based ADC is a desirable strategy for developing the next generation of ADCs for research, diagnostic, and therapeutic purposes. Our comprehensive solution offers an optimal and highly effective approach to achieving your objectives
with a significant success rate. With the help of highly experienced staff, Creative Biolabs offers different sdAb-based conjugates based on radioactive tracers, nanomaterials, gene products, immunomodulatory, cytotoxic reagents, or a combination.
The new generation of sdAb-based ADCs showed remarkable targetability, higher antitumor efficacy, and low systemic side effects in therapeutic and diagnostic applications, especially for improving targeted delivery. In summary, we will offer a promising
platform to generate sdAb-based ADCs, which will show remarkable targetability, higher antitumor efficacy, and low systemic side effects in both therapeutic and diagnostic applications, especially for improving targeted delivery.
Typical Pathway for SdAb-based ADC Development
Phase I Discovery
Target Identification Multiple target identification processes can be provided upon your request.
Phase II Characterization
Phase III Development
VHH-Drug Conjugate Development
Typical Features of One-Stop for SdAb-based ADC Development
-
State-of-the-art technical platform for addressing challenging targets.
-
Holistic approaches to develop optimal solutions for sdAb-based ADCs.
-
Seasoned professional team possessing extensive expertise.
-
Entirely customizable proposal to fulfill specific requirements.
-
Fast turnaround time.
-
Dependable laboratory report with prompt updates.
-
Affordable price with the best quality.
Creative Biolabs is committed to supporting sdAb-based ADC development projects with exceptional quality and efficiency. Leveraging our robust platform and experienced scientists, we are confident in providing tailored, comprehensive
solutions to meet your specific needs. For further information, please do not hesitate to contact us.
We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.